LT3359185T - Priešnavikinė kompozicija - Google Patents

Priešnavikinė kompozicija

Info

Publication number
LT3359185T
LT3359185T LTEPPCT/FR2016/052598T LT16052598T LT3359185T LT 3359185 T LT3359185 T LT 3359185T LT 16052598 T LT16052598 T LT 16052598T LT 3359185 T LT3359185 T LT 3359185T
Authority
LT
Lithuania
Prior art keywords
cumor
composition
cumor composition
Prior art date
Application number
LTEPPCT/FR2016/052598T
Other languages
English (en)
Inventor
Jean-Marc Limacher
Original Assignee
Jean-Marc Limacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean-Marc Limacher filed Critical Jean-Marc Limacher
Publication of LT3359185T publication Critical patent/LT3359185T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/FR2016/052598T 2015-10-08 2016-10-07 Priešnavikinė kompozicija LT3359185T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1559589A FR3042121A1 (fr) 2015-10-08 2015-10-08 Composition anti-tumorale
FR1659450A FR3042122B1 (fr) 2015-10-08 2016-09-30 Composition anti-tumorale
PCT/FR2016/052598 WO2017060650A1 (fr) 2015-10-08 2016-10-07 Composition anti-tumorale

Publications (1)

Publication Number Publication Date
LT3359185T true LT3359185T (lt) 2022-06-27

Family

ID=55178130

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/FR2016/052598T LT3359185T (lt) 2015-10-08 2016-10-07 Priešnavikinė kompozicija

Country Status (14)

Country Link
US (2) US20180296653A1 (lt)
EP (1) EP3359185B1 (lt)
JP (1) JP7211815B2 (lt)
KR (1) KR20180059547A (lt)
CN (1) CN108348587A (lt)
CA (1) CA2999948C (lt)
DK (1) DK3359185T3 (lt)
ES (1) ES2919134T3 (lt)
FR (2) FR3042121A1 (lt)
HK (1) HK1253315A1 (lt)
IL (1) IL258430B (lt)
LT (1) LT3359185T (lt)
RU (1) RU2728748C2 (lt)
WO (1) WO2017060650A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
AU2021301922A1 (en) * 2020-06-30 2023-02-02 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP0951555A2 (en) 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU754386B2 (en) 1997-09-23 2002-11-14 Bavarian Nordic A/S Dengue virus antigens and treatment of dengue fever
RU2280075C2 (ru) 2000-03-14 2006-07-20 Бавариан Нордик А/С Измененный штамм модифицированного вируса коровьей оспы ankara (mva)
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
AU2002356690B2 (en) 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
ATE300954T1 (de) 2001-12-10 2005-08-15 Bavarian Nordic As Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
US7056723B2 (en) 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
DK1420822T4 (en) 2002-04-19 2017-10-09 Bavarian Nordic As Modified vaccinia virus Ankara for vaccination of newborns
CA2481783A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
KR20100063126A (ko) 2002-05-16 2010-06-10 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
PL218318B1 (pl) 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
AU2003293675B2 (en) 2002-11-25 2009-04-23 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ATI promoters
US7785778B2 (en) 2002-11-25 2010-08-31 University Of Copenhagen Porcine polymorphisms and methods for detecting them
US20050112099A1 (en) * 2003-04-15 2005-05-26 Aventis Pasteur, Ltd. Tumor antigen BFA5 for prevention and / or treatment of cancer
DE602004009743T2 (de) 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
UA100836C2 (ru) 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
EP2064351A1 (en) 2006-09-08 2009-06-03 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
EP2073837B1 (en) 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
CA2676808C (en) 2007-04-27 2016-08-02 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf)
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US7867483B2 (en) 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
CN102124029A (zh) * 2008-05-26 2011-07-13 泰里安诊断有限公司 诊断由分枝杆菌引起的感染的方法和针对其的试剂
US20110052627A1 (en) 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
WO2010057650A1 (en) 2008-11-21 2010-05-27 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
AU2011209175B2 (en) 2010-01-28 2016-02-04 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of MVA
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
CA2815727C (en) 2010-11-05 2019-09-10 Bavarian Nordic A/S Modulation of immune responses by the poxviral k4 protein
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
US10973892B2 (en) 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
WO2014063832A1 (en) 2012-10-28 2014-05-01 Bavarian Nordig A/S Pr13.5 promoter for robust t-cell and antibody responses
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
CA2928199C (en) * 2013-11-05 2025-06-17 Bavarian Nordic A/S POLYTHERAPY FOR CANCER TREATMENT USING A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR
NZ721908A (en) * 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
CN107847534B (zh) * 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用

Also Published As

Publication number Publication date
IL258430B (en) 2022-03-01
RU2018115534A (ru) 2019-11-08
IL258430A (en) 2018-06-28
DK3359185T3 (da) 2022-07-04
CA2999948C (fr) 2024-04-23
JP2018531238A (ja) 2018-10-25
EP3359185A1 (fr) 2018-08-15
FR3042122B1 (fr) 2020-01-17
JP7211815B2 (ja) 2023-01-24
HK1253315A1 (zh) 2019-06-14
CA2999948A1 (fr) 2017-04-13
KR20180059547A (ko) 2018-06-04
EP3359185B1 (fr) 2022-04-06
FR3042121A1 (fr) 2017-04-14
CN108348587A (zh) 2018-07-31
RU2728748C2 (ru) 2020-07-31
ES2919134T3 (es) 2022-07-22
US20180296653A1 (en) 2018-10-18
US20210138053A1 (en) 2021-05-13
FR3042122A1 (fr) 2017-04-14
WO2017060650A1 (fr) 2017-04-13
RU2018115534A3 (lt) 2020-02-26

Similar Documents

Publication Publication Date Title
EP3493800A4 (en) CANNABIS
DK3361870T3 (da) Fungicidsammensætninger
DK3416996T3 (da) Hærdelig sammensætning
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3542812T3 (da) Glycopeptidsammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3528902T3 (da) Ringegelsammensætning
EP3430073A4 (en) COMPOSITION BASED ON A POLYARYLETHERKETONE COMPOSITION
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
CL2017000639A1 (es) Composición
EP3480228A4 (en) COMPOSITION
DK3331498T3 (da) Nasalsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
EP3556804A4 (en) COMPOSITION
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (en) COMPOSITION
EP3236746C0 (en) COMPOSITION
DE102015206660A8 (de) Plattenaufteilanlage
EP3524627A4 (en) COMPOSITION